Elicio Therapeutics reports developments as a clinical-stage biotechnology company developing cancer immunotherapies. Company news centers on its proprietary Amphiphile, or AMP, technology, the ELI-002 program, and immunotherapy work for mKRAS-positive cancers including pancreatic ductal adenocarcinoma, colorectal cancer, lung cancer, and other KRAS-driven tumors.
Recurring updates also include clinical and regulatory disclosures, operating and financial results, healthcare-conference presentations, shareholder voting and governance matters, capital-structure actions, and Nasdaq inducement stock option grants under the company’s 2024 Inducement Incentive Award Plan.
Elicio Therapeutics (Nasdaq: ELTX) will present additional Phase 2 AMPLIFY-7P results at the SITC annual meeting on November 4–8, 2026.
The meeting in Phoenix will include a November 6 keynote/plenary presentation on camupepimut (ELI-002 7P) and a November 7 late-breaking poster on the randomized trial. AMPLIFY-7P enrolled 144 patients across 24 U.S. clinical sites and compares camupepimut with observation in KRAS-mutated pancreatic cancer following standard locoregional therapy. A separate November 7 preclinical poster will cover direct injection of AMP-platform immunomodulators into tumors.
Elicio Therapeutics (ELTX) reported that camupepimut missed the primary disease-free survival endpoint in its randomized Phase 2 pancreatic cancer study. AMPLIFY-7P enrolled 144 patients; the overall hazard ratio, a comparison of event risk, was 0.85. Results were presented at ESMO Congress 2026 and published in Nature Medicine.
Pre-specified subgroups favored treatment: hazard ratios were 0.51 without detectable baseline circulating tumor DNA (ctDNA), 0.57 with detectable ctDNA and 0.59 without prior radiation. Baseline ctDNA positivity was more common with treatment than observation, 20.8% versus 12.5%; a model adjusting for baseline factors estimated a treatment-associated hazard ratio of 0.47. Elicio plans FDA discussions about a potential Phase 3 study, including patient selection, treatment duration and combinations. Future design remains subject to regulatory discussion and development planning.
Elicio Therapeutics (ELTX) will present new Phase 2 AMPLIFY-7P analyses at ESMO Congress on October 23, 2026.
The randomized study compared investigational ELI-002 7P with observation in patients with KRAS-mutated pancreatic ductal adenocarcinoma after standard therapy. It enrolled 144 patients at 24 U.S. sites and did not meet its prespecified primary disease-free survival endpoint in the intent-to-treat population. The presentation will cover new prespecified analyses. Elicio expects the findings to inform its planning for a potential Phase 3 study in pancreatic cancer after surgery.
The late-breaking presentation is scheduled for October 23 in Madrid. Abstract LBA83 will be available on the ESMO Congress website beginning at 00:05 CEST that day. A session webcast is subject to presenter permission and, if permitted, will be available on the congress’s virtual platform within 12 hours after the session.
Elicio Therapeutics (Nasdaq: ELTX) announced that CEO Robert Connelly and CSO Pete DeMuth will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York. The session is scheduled for Monday, September 14, 2026, at 2:00 PM ET, with a live webcast and 90-day replay available via Elicio’s Events page. Interested attendees can request 1×1 meetings with management through their H.C. Wainwright representative.
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech developing immunotherapies for KRAS-driven cancers, announced that its management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference, held September 8-10, 2026, in Boston, MA. One-on-one meetings are scheduled for Thursday, September 10, 2026, and interested parties are asked to contact their Wells Fargo representative to arrange a meeting.
Elicio Therapeutics (Nasdaq: ELTX) reported second quarter 2026 results and clinical updates focused on its lead KRAS-targeted immunotherapy ELI-002 7P. Multiple complete responses were observed following ELI-002 7P treatment and subsequent checkpoint inhibition in metastatic mKRAS pancreatic cancer, supporting a planned Phase 1 combination study with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor, anticipated to start in Q4 2026.
The Phase 2 AMPLIFY-7P adjuvant PDAC trial did not meet its primary endpoint, and Elicio is analyzing pre-specified subgroups to inform Phase 3 strategy. An investigator-initiated neoadjuvant Phase 1 trial led by Memorial Sloan Kettering has been activated. Elicio completed a $15 million July 2026 financing and raised $24.4 million year to date via its ATM, ending June 30 with $23.5 million in cash and cash equivalents and expecting runway into Q1 2027. Q2 2026 R&D was $6.8 million, G&A $3.6 million, and net loss $8.2 million, or $0.43 per share.
Elicio Therapeutics (Nasdaq: ELTX) announced activation of an investigator-initiated, randomized, open-label Phase 1 neoadjuvant trial (NCT07671339) of its AMP-based KRAS-targeted immunotherapy ELI-002 7P in resectable and borderline resectable KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). The multi-center study, conducted by Memorial Sloan Kettering Cancer Center and funded by a partnership between The Lustgarten Foundation and Break Through Cancer, aims to enroll 20 patients.
Patients will receive ELI-002 7P with standard neoadjuvant chemotherapy mFOLFIRINOX, with or without the anti-PD1 checkpoint inhibitor tislelizumab, starting before surgery and continuing afterward. The study will collect tumor and blood samples to assess immune activation, tumor microenvironment changes and potential biomarkers to guide future trials. ELI-002 7P, covering seven common KRAS mutations present in about 25% of solid tumors, has previously been evaluated in the Phase 2 AMPLIFY-7P trial in high-risk mKRAS-positive pancreatic cancer, where overall survival data remained immature at the time of analysis. Elicio is also planning additional ELI-002 7P studies in metastatic and adjuvant PDAC and other mKRAS-positive cancers.
Elicio Therapeutics (Nasdaq: ELTX) closed a previously announced registered direct offering of 4,380,313 common shares, raising approximately $15 million in gross proceeds before fees.
The company plans to use funds to support Phase 1 development of ELI-002 7P in metastatic PDAC, advance its pipeline and platform, and for working capital and general corporate purposes.
Elicio Therapeutics (Nasdaq: ELTX) priced a registered direct offering of 4,380,313 common shares, led by two new institutional investors and a large existing shareholder. The deal is expected to raise about $15 million in gross proceeds, closing around July 6, 2026, subject to customary conditions.
According to Elicio, net proceeds plus existing cash will primarily fund planned Phase 1 development of ELI-002 7P in metastatic PDAC, its broader pipeline and platform, and general corporate purposes.
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech developing immunotherapies for KRAS-driven cancers, has been added to the Russell 2000 and Russell 3000 indexes, effective after the U.S. market close on June 26, 2026, following the 2026 Russell reconstitution.
The company views this as a milestone that broadens visibility with institutional investors as it advances its ELI-002 7P program.